Antengene Corporation Limited ('Antengene', SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or ...

Chair of the Board at Transamerica brings decades of global insurance and financial services leadership to support Ethos’ ...

Discover how Pitavastatin, a cholesterol-lowering drug, shows promise as a treatment for triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is among the most aggressive types of breast cancer, lacking estrogen, progesterone, and ...

Triple-negative breast cancer (TNBC) is among the most aggressive types of breast cancer, lacking estrogen, progesterone, and HER2 receptors and thus relying primarily on cytotoxic chemotherapy.

Metastasis occurs when cancer cells break away from the original tumor and travel through the bloodstream to form new tumors in other parts of the body. It is the leading cause of cancer-related death ...

Objective: Breast cancer remains the leading cause of cancer-associated death for women globally. For the group of ER+ breast cancer patients, there are still some problems of poor prognosis that need ...

Two molecular targets-human epidermal growth factor 2 (HER2) and cluster of differentiation 24 (CD24)-are highly promising candidates for new nuclear diagnostics and therapeutics for endometrial ...

Reston, VA (September 4, 2025)—Two molecular targets—human epidermal growth factor 2 (HER2) and cluster of differentiation 24 (CD24)—are highly promising candidates for new nuclear diagnostics and ...

The FDA granted fast track designation to PHST001 for the treatment of advanced ovarian cancer. PHST001, an investigational anti-CD24 monoclonal antibody, received FDA fast track designation for ...

PHST001 targets CD24, a protein that helps tumors evade immune destruction, potentially enhancing immune response against cancer cells. The FDA's fast track designation accelerates the development and ...